iDenfy’s revamped AML Screening software now includes new risk categories, better PEP status labeling, and other built-in AML features Delaware, United States, October 29, 2025-- iDenfy, a global ...
A panelist discusses how ASCO 2025's most important breakthrough was the oral decitabine plus venetoclax combination, representing a potential paradigm shift if approved by the FDA, while highlighting ...
Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...
Have you given a thought to Anti-Money Laundering (AML) compliance? If not, now’s the time, because UK regulators are tightening the screws. According ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback